Literature DB >> 22923018

Abandoning "TAP" as treatment of metastatic endometrial cancer: a serious example of the consequences resulting from the failure to adequately define the question being addressed in a phase 3 trial.

Maurie Markman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22923018     DOI： 10.1007/s11912-012-0264-6

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


× No keyword cloud information.
  17 in total

1.  Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.

Authors:  M J Piccart; K Bertelsen; K James; J Cassidy; C Mangioni; E Simonsen; G Stuart; S Kaye; I Vergote; R Blom; R Grimshaw; R J Atkinson; K D Swenerton; C Trope; M Nardi; J Kaern; S Tumolo; P Timmers; J A Roy; F Lhoas; B Lindvall; M Bacon; A Birt; J E Andersen; B Zee; J Paul; B Baron; S Pecorelli
Journal:  J Natl Cancer Inst       Date:  2000-05-03       Impact factor: 13.506

2.  A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study.

Authors:  H G Ball; J A Blessing; S S Lentz; D G Mutch
Journal:  Gynecol Oncol       Date:  1996-08       Impact factor: 5.482

3.  Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study.

Authors:  P J Hoskins; K D Swenerton; J A Pike; F Wong; P Lim; C Acquino-Parsons; N Lee
Journal:  J Clin Oncol       Date:  2001-10-15       Impact factor: 44.544

4.  Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study.

Authors:  J Tate Thigpen; Mark F Brady; Howard D Homesley; John Malfetano; Brent DuBeshter; Robert A Burger; Shu Liao
Journal:  J Clin Oncol       Date:  2004-10-01       Impact factor: 44.544

5.  Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study.

Authors:  W P McGuire; W J Hoskins; M F Brady; H D Homesley; W T Creasman; M L Berman; H Ball; J S Berek; J Woodward
Journal:  J Clin Oncol       Date:  1995-07       Impact factor: 44.544

6.  Ovarian cancer.

Authors:  Bryan T Hennessy; Robert L Coleman; Maurie Markman
Journal:  Lancet       Date:  2009-09-28       Impact factor: 79.321

7.  High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest.

Authors:  P F Conte; M Bruzzone; F Carnino; A Gadducci; R Algeri; A Bellini; F Boccardo; I Brunetti; E Catsafados; S Chiara; G Foglia; L Gallo; L Iskra; S Mammoliti; G Parodi; N Ragni; R Rosso; S Rugiati; A Rubagotti
Journal:  J Clin Oncol       Date:  1996-02       Impact factor: 44.544

8.  Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group.

Authors:  M Gore; P Mainwaring; R A'Hern; V MacFarlane; M Slevin; P Harper; R Osborne; J Mansi; P Blake; E Wiltshaw; J Shepherd
Journal:  J Clin Oncol       Date:  1998-07       Impact factor: 44.544

9.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.

Authors:  W P McGuire; W J Hoskins; M F Brady; P R Kucera; E E Partridge; K Y Look; D L Clarke-Pearson; M Davidson
Journal:  N Engl J Med       Date:  1996-01-04       Impact factor: 91.245

Review 10.  Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration.

Authors:  C E Humber; J F Tierney; R P Symonds; M Collingwood; J Kirwan; C Williams; J A Green
Journal:  Ann Oncol       Date:  2006-12-05       Impact factor: 32.976
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.